Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses

Biochemical Pharmacology

Volumn 104, Issue , 2016, Pages 42-51

  Kadioglu, Onat ^a   Saeed, Mohamed E M ^a   Valoti, Massimo ^b   Frosini, Maria ^b   Sgaragli, Giampietro ^b   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Cancer drug resistance; Molecular docking; N,N Bis(cyclohexanolamine)aryl ester; P glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOSPORIN A; ELACRIDAR; EPIRUBICIN; ESTER DERIVATIVE; LYSINE; MULTIDRUG RESISTANCE PROTEIN 1; N,N BIS(CYCLOHEXANOLAMINE)ARYL ESTER; PROTEIN INHIBITOR; RHODAMINE 123; SERINE; TYROSINE; UNCLASSIFIED DRUG; VALSPODAR; CYCLOHEXANOL DERIVATIVE; ESTER; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; HYDROGEN BOND; LYMPHOMA; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL CULTURE TECHNIQUE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; GENETIC TRANSFECTION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; BINDING SITES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYCLOHEXANOLS; EPIRUBICIN; ESTERS; MICE; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; PROTEIN BINDING; PROTEIN TRANSPORT; RHODAMINE 123; SUBSTRATE SPECIFICITY; TRANSFECTION;

EID: 84959573386     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.01.014     Document Type: Article

References (46)

1. E. Jabbour, J.E. Cortés, and H. Kantarjian Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure Clin. Lymphoma Myeloma 9 Suppl. 3 2009 S272 S279
2. A. Eghtedar, H. Kantarjian, E. Jabbour, S. O'Brien, E. Burton, G. Garcia-Manero, S. Verstovsek, F. Ravandi, G. Borthakur, M. Konopleva, A. Quintas-Cardama, and J. Cortes Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia Clin. Lymphoma Myeloma Leuk. 13 2013 477 484
3. T. Efferth The human ATP-binding cassette transporter genes: from the bench to the bedside Curr. Mol. Med. 1 2001 45 65
4. M.M. Gottesman, and V. Ling The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research FEBS Lett. 580 2006 998 1009
5. J.P. Gillet, T. Efferth, and J. Remacle Chemotherapy-induced resistance by ATP-binding cassette transporter genes Biochim. Biophys. Acta 1775 2007 237 262
6. M. Volm, and T. Efferth Role of P-glycoprotein for resistance of tumors to anticancer drugs: from bench to bedside T. Efferth, Resistance to Targeted Anti-cancer Therapeutics 2015 Springer New York 1 26
7. V. Kuete, H. Fouotsa, A.T. Mbaveng, B. Wiench, A.E. Nkengfack, and T. Efferth Cytotoxicity of a naturally occurring furoquinoline alkaloid and four acridone alkaloids towards multi-factorial drug-resistant cancer cells Phytomedicine 22 2015 946 951
8. T. Efferth, M. Zeino, and M. Volm Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids T. Efferth, Resistance to Targeted Anti-cancer Therapeutics 2015 Springer New York 153 181
9. S.A. Abdelfatah, and T. Efferth Cytotoxicity of the indole alkaloid reserpine from Rauwolfia serpentina against drug-resistant tumor cells Phytomedicine 22 2015 308 318
10. S.G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P.M. Harrell, Y.T. Trinh, Q. Zhang, I.L. Urbatsch, and G. Chang Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 323 2009 1718 1722
11. A. Neri, M. Frosini, M. Valoti, M.G. Cacace, E. Teodori, and G. Sgaragli N,N-bis(cyclohexanol)amine aryl esters inhibit P-glycoprotein as transport substrates Biochem. Pharmacol. 82 2011 1822 1831
12. E. Teodori, S. Dei, A. Garnier-Suillerot, F. Gualtieri, D. Manetti, C. Martelli, M.N. Romanelli, S. Scapecchi, P. Sudwan, and M. Salerno Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models J. Med. Chem. 48 2005 7426 7436
13. C. Martelli, D. Alderighi, M. Coronnello, S. Dei, M. Frosini, B. Le Bozec, D. Manetti, A. Neri, M.N. Romanelli, M. Salerno, S. Scapecchi, E. Mini, G. Sgaragli, and E. Teodori N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors J. Med. Chem. 52 2009 807 817
14. C. Martelli, S. Dei, C. Lambert, D. Manetti, F. Orlandi, M.N. Romanelli, S. Scapecchi, M. Salerno, and E. Teodori Inhibition of P-glycoprotein-mediated Multidrug Resistance (MDR) by N,N-bis(cyclohexanol)amine aryl esters: further restriction of molecular flexibility maintains high potency and efficacy Bioorg. Med. Chem. Lett. 21 1 2011 106 109
15. I. Pastan, M.M. Gottesman, K. Ueda, E. Lovelace, A.V. Rutherford, and M.C. Willingham A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells Proc. Natl. Acad. Sci. U.S.A. 85 1988 4486 4490
16. J.L. Weaver, G. Szabo Jr., P.S. Pine, M.M. Gottesman, S. Goldenberg, and A. Aszalos The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter Int. J. Cancer 54 3 1993 May 28 456 461
17. E.J. Wang, C.N. Casciano, R.P. Clement, and W.W. Johnson In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein Drug Metab. Dispos. 28 5 2000 May 522 528
18. S. Saponara, M. Kawase, A. Shah, N. Motohashi, J. Molnar, K. Ugocsai, G. Sgaragli, and F. Fusi 3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility Br. J. Pharmacol. 141 3 2004 Feb 415 422
19. M. Kawase, A. Shah, H. Gaveriya, N. Motohashi, H. Sakagami, A. Varga, and J. Molnár 3,5-Dibenzoyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells Bioorg. Med. Chem. 10 2002 1051 1055
20. Y. Tajima, H. Nakagawa, A. Tamura, O. Kadioglu, K. Satake, Y. Mitani, H. Murase, L.O. Regasini, S. Bolzani Vda, T. Ishikawa, G. Fricker, and T. Efferth Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1 Phytomedicine 21 2014 323 332
21. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility J. Comput. Chem. 30 2009 2785 2791
22. I.W. Kim, X.H. Peng, Z.E. Sauna, P.C. FitzGerald, D. Xia, M. Müller, K. Nandigama, and S.V. Ambudkar The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: evidence for a conserved subdomain, the A-loop in the ATP-binding cassette Biochemistry 45 2006 7605 7616
23. Z.E. Sauna, and S.V. Ambudkar About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work Mol. Cancer Ther. 6 2007 13 23
24. D.A. Gutmann, A. Ward, I.L. Urbatsch, G. Chang, and H.W. van Veen Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1 Trends Biochem. Sci. 35 2010 36 42
25. Y. Shamsudin Khan, H. Gutiérrez-de-Terán, L. Boukharta, and J. Åqvist Toward an optimal docking and free energy calculation scheme in ligand design with application to COX-1 inhibitors J. Chem. Inf. Model. 54 2014 1488 1499
26. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
27. M. Kunihara, J. Nagai, T. Murakami, and M. Takano Renal excretion of rhodamine 123, a P-glycoprotein substrate, in rats with glycerol-induced acute renal failure J. Pharm. Pharmacol. 50 1998 1161 1165
28. M.M. Pires, C.A. Hrycyna, and J. Chmielewski Bivalent probes of the human multidrug transporter P-glycoprotein Biochemistry 45 2006 11695 11702
29. S. Dey, M. Ramachandra, I. Pastan, M.M. Gottesman, and S.V. Ambudkar Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein Proc. Natl. Acad. Sci. U.S.A. 94 1997 10594 10599
30. C. Martin, G. Berridge, P. Mistry, C. Higgins, P. Charlton, and R. Callaghan Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis Biochemistry 39 2000 11901 11906
31. C. Marbeuf-Gueye, M. Salerno, P. Quidu, and A. Garnier-Suillerot Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P Eur. J. Pharmacol. 391 2000 207 216
32. T.W. Loo, M.C. Bartlett, and D.M. Clarke Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein J. Biol. Chem. 278 2003 39706 39710
33. A.B. Shapiro, and V. Ling Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Eur. J. Biochem. 254 1988 189 193
34. S.V. Ambudkar, C.O. Cardarelli, I. Pashinsky, and W.D. Stein Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein J. Biol. Chem. 272 1997 21160 21166
35. C.E. Liu, P.Q. Liu, and G.F. Ames Characterization of the adenosine triphosphatase activity of the periplasmic histidine permease, a traffic ATPase (ABC transporter) J. Biol. Chem. 272 1997 21883 21891
36. M.L. Mimmack, M.P. Gallagher, S.R. Pearce, S.C. Hyde, I.R. Booth, and C.F. Higgins Energy coupling to periplasmic binding protein-dependent transport systems: stoichiometry of ATP hydrolysis during transport in vivo Proc. Natl. Acad. Sci. U.S.A. 86 1989 8257 8261
37. C.A. Hrycyna, M. Ramachandra, U.A. Germann, P.W. Cheng, I. Pastan, and M.M. Gottesman Both ATP sites of human P-glycoprotein are essential but not symmetric Biochemistry 38 1999 13887 13899
38. Z.E. Sauna, and S.V. Ambudkar Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein Proc. Natl. Acad. Sci. U.S.A. 97 2000 2515 2520
39. R.K. Emaus, R. Grunwald, and J.J. Lemasters Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties Biochim. Biophys. Acta 850 1986 436 448
40. G. Szakács, M.D. Hall, M.M. Gottesman, A. Boumendjel, R. Kachadourian, B.J. Day, H. Baubichon-Cortay, and A. Di Pietro Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance Chem. Rev. 114 2014 5753 5774
41. M. Zeino, M.E. Saeed, O. Kadioglu, and T. Efferth The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein-a well-known, yet poorly understood drug transporter Invest. New Drugs 32 2014 618 625
42. A. Tamaki, C. Ierano, G. Szakacs, R.W. Robey, and S.E. Bates The controversial role of ABC transporters in clinical oncology Essays Biochem. 50 2011 209 232
43. L. Amiri-Kordestani, A. Basseville, K. Kurdziel, A.T. Fojo, and S.E. Bates Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies Drug Resist. Updates 15 2012 50 61
44. B.C. Shaffer, J.P. Gillet, C. Patel, M.R. Baer, S.E. Bates, and M.M. Gottesman Drug resistance: still a daunting challenge to the successful treatment of AML Drug Resist. Updates 15 2012 62 69
45. M. Saeed, M. Zeino, O. Kadioglu, M. Volm, and T. Efferth Overcoming of P-glycoprotein-mediated multidrug resistance of tumors in vivo by drug combinations Synergy 1 2014 44 58
46. T. Saeki, T. Nomizu, M. Toi, Y. Ito, S. Noguchi, T. Kobayashi, T. Asaga, H. Minami, N. Yamamoto, K. Aogi, T. Ikeda, Y. Ohashi, W. Sato, and T. Tsuruo Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer J. Clin. Oncol. 25 2007 411 417